A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
- 1 January 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (1) , 57-63
- https://doi.org/10.1016/s0959-8049(01)00188-5
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II TrialsJournal of Clinical Oncology, 2000
- Topotecan: tolerability, response rate and survival associated with extended therapy in relapsed ovarian cancer — Results of a pooled analysis of 523 patientsEuropean Journal Of Cancer, 1999
- Oral topotecan: bioavailability and effect of food co-administrationBritish Journal of Cancer, 1999
- Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of Clinical Oncology, 1998
- Improving the Quality of Reporting of Randomized Controlled TrialsJAMA, 1996
- Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitorBritish Journal of Cancer, 1996
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992
- Ovarian carcinoma.Advances in diagnosis, staging, and treatmentCancer, 1990